Project description
Tracing the capabilities of pharmacogenetics in psychiatric treatment
Despite the continuous development of treatments for patients with mental illness, crucial factors such as genetic heterogeneity, low compliance and commonly encountered side effects limit treatment efficacy. In contrast with the widespread practice of selecting medication through trial and error, pharmacogenetic testing enables the evaluation of person-specific factors that make the clinical response and side effects foreseeable. The EU-funded PSY-PGx project is introducing a large-scale non-industry sponsored clinical study in 6 European (related) countries and the US that demonstrates the clinical benefits and the potential of implementing pharmacogenetics for psychiatric patients in existing medical settings.
Objective
Due to the chronic relapsing nature of mental disorders and increased life expectancy, the societal burden of these non-communicable diseases will increase even further. Treatments for mental disorders are available, but their effect is limited due to patients’ (genetic) heterogeneity, low treatment compliance and frequent side effects. Only one-third of the patients respond to treatment. Today, medication selection in psychiatry relies on a trial-and-error approach based mainly on physicians’ experience. Pharmacogenetic testing enables assessing person-specific genetic factors that predict clinical response and side effects. Recent studies show that genotyping of drug-metabolizing enzymes can increase the effectiveness of treatment, which could benefit millions of patients. PSY-PGx is the first initiative to propose a large-scale non-industry sponsored clinical study that demonstrates the clinical benefits and potential of implementing pharmacogenetics for psychiatric patients in existing medical settings. To this end 1) available biobank data (www.biobankki.fi www.ukbiobank.ac.uk) with the aid of AI, will be searched for pharmacogenetics that influence medication response. This information is used to 2) perform a clinical trial that will be the first large international, multicenter clinical trial on using pharmacogenetic-based treatment personalization in real-life psychiatric care for depressed, anxiety or psychotic disorder patients. All data is combined with AI to set-up an algorithm for personalizing medication prescription for psychiatric patients that reduces side effects and increases effectiveness of pharmacotherapy. PSY-PGx will thus deliver a new model of care for sustainable healthcare systems and reduce the suffering of psychiatric patients.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6200 MD Maastricht
Netherlands
See on map
Participants (17)
9712CP Groningen
See on map
81669 Munchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
11010 BELGRADE
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
11000 Beograd
See on map
53127 Bonn
See on map
400084 Cluj Napoca
See on map
00014 Helsingin Yliopisto
See on map
2553 RJ Den Haag
See on map
1226 THONEX
See on map
17177 Stockholm
See on map
69978 Tel Aviv
See on map
12201 Albany Ny
See on map
80539 MUNCHEN
See on map
WC2R 2LS London
See on map
08036 Barcelona
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
08036 Barcelona
See on map
1050 Bruxelles / Brussel
See on map